Drug Sponsors

Chelsea Therapeutics implements $6M cost savings to expand Northera study

Monday, June 11, 2012 12:18 PM

Chelsea Therapeutics International, biopharmaceutical development company, reports that all corporate officers and members of its board of directors volunteered to receive a 25% reduction in compensation until data from its ongoing phase III study of Northera (droxidopa) is available.

More... »

InnoPharma raises $8M in venture debt

Monday, June 11, 2012 12:04 PM

InnoPharma, a sterile product development company of Piscataway, N.J., has closed on an $8 million growth capital financing from Comerica Bank and NXT Capital Venture Finance.

More... »

Modulation Therapeutics receives $500,000 from MMRF for cancer treatment

Monday, June 11, 2012 11:54 AM

The Multiple Myeloma Research Foundation (MMRF) has awarded $500,000 through its Biotech Investment Award (BIA) program to Modulation Therapeutics, an early-stage pharmaceutical company which has licensed MTI-101 from the Moffitt Cancer Center.

More... »

Navidea Biopharmaceuticals opens new facility in Andover, Mass.

Monday, June 11, 2012 10:43 AM

Navidea Biopharmaceuticals, a Dublin, Ohio-based specialty biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, has opened its new business and commercialization facility in Andover, Mass.

More... »

GSK extends tender offer for HGS shares

Monday, June 11, 2012 09:49 AM

GlaxoSmithKline has extended its tender offer to acquire all of the outstanding shares of Human Genome Sciences for $13.00 per share in cash to 5:00 p.m. EST on Friday, June 29, 2012. The tender offer was previously scheduled to expire at 12:00 midnight EST, at the end of the day on June 7, 2012.

More... »

Foundation Medicine to provide Novartis with genetic info for oncology programs

Friday, June 8, 2012 01:00 PM

Molecular information company Foundation Medicine has extended its pilot program with Novartis to provide comprehensive genomic analysis in support of Novartis' clinical oncology programs.

More... »

OICR funds Fluorinov Pharma to develop drug for blood cancers

Thursday, June 7, 2012 12:42 PM

The Ontario Institute for Cancer Research (OICR) will invest $1.5 million over three years for the development of a novel drug by Toronto-based Fluorinov Pharma.

More... »

PhaseBio raises additional $23M in Series B financing

Thursday, June 7, 2012 12:05 PM

PhaseBio Pharmaceuticals, a Malvern, Penn.-based, privately-held, clinical-stage biotechnology company developing drugs to treat diabetes, metabolic disease and cardiovascular disease, has raised a total of $48.4 million from its Series B financing following receipt of the third tranche to advance the company's product development programs.

More... »

Baxter collaborates with Chatham on Hemophilia B gene therapy

Wednesday, June 6, 2012 01:31 PM

Baxter International, a global, diversified healthcare company, has entered into an exclusive global agreement with Chatham Therapeutics, a private clinical development-stage biotech, for the development and commercialization of  potential treatments for hemophilia B utilizing Chatham's gene therapy technology. 

More... »

Dr. Reddy's and Merck Serono collaborate on biosimilars

Wednesday, June 6, 2012 01:07 PM

Dr. Reddy's Laboratories, an integrated global pharmaceutical company, and Merck Serono, a division of Merck, have formed a partnership to co-develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies (MAbs).

More... »